Market Cap (In USD)
193.39 Million
Revenue (In USD)
-
Net Income (In USD)
-149.68 Million
Avg. Volume
97.49 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.02-0.105
- PE
- -
- EPS
- -
- Beta Value
- 3.34
- ISIN
- AU000000IMU9
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Leslie Chong
- Employee Count
- -
- Website
- https://www.imugene.com
- Ipo Date
- 2019-07-05
- Details
- Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
More Stocks
-
PLXSPlexus Corp.
PLXS
-
2472
-
AGIAlamos Gold Inc.
AGI
-
PTWO
-
SAPR3
-
3705
-
PLUSePlus inc.
PLUS
-
1513